NSE: NH | BSE: 539551

Mid-range Performer

Download real time

1731.50 -6.10 (-0.35%)

26.95% Fall from 52W High

276.0K NSE+BSE Volume

NSE 01 Oct, 2025 3:31 PM (IST)

35,385.1

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Narayana Hrudayalaya Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NH, BSE:539551 Narayana Hrudayalaya Ltd.

Search Inside the pdf :

Narayana Hrudayalaya Ltd.

20 Aug 2025

1731.50

-0.35%

NARAYANA HRUDAYALAYA LIMITED

Sell: Narayana Hrudayalaya Ltd.

Target

Geojit BNP Paribas

In Q1FY26, Narayana Hrudayalaya delivered stable topline performance, though EBITDA margins were impacted by losses in the Integrated Care segment. The segment remains dilutive, with elevated costs weighing on consolidated profitability. With a pipeline of...

Narayana Hrudayalaya Ltd. is trading above its 200 day SMA of 1674.2

Narayana Hrudayalaya Ltd.

11 Aug 2025

1731.50

-0.35%

Losses from CIHL drag on overall performance; maintaining a Buy

Buy: Narayana Hrudayalaya Ltd.

Target

Anand Rathi

Below our estimate (mainly losses at Cayman Integrated Healthcare), Narayana Hrudayalaya’s Q1 EBITDA was Rs3.4bn, up 11% y/y, 7% q/q.

Number of FII/FPI investors increased from 277 to 335 in Jun 2025 qtr.

Narayana Hrudayalaya Ltd.

05 Aug 2025

1731.50

-0.35%

Narayana Hrudayalaya (NARH IN) Q1FY26 Result Update EBITDA...

Buy: Narayana Hrudayalaya Ltd.

Target

Prabhudas Lilladhar

Narayana Hrudayalaya (NARH) reported EBITDA of Rs3.4bn (up 11% YoY) in Q1FY26, 4% below our estimates due to losses at Cayman Integrated Healthcare business. The Cayman business reported profitability of Rs1.44bn (up 17% YoY), adjusted for CIHL losses, up 25% YoY. India business reported healthy EBITDA adjusted for NHIC losses, up 13% YoY. The management reiterated its aggressive capex plan and commitment towards growing throughput over the next 3-4 years through debottlenecking, refurbishment...

Number of FII/FPI investors increased from 277 to 335 in Jun 2025 qtr.

Narayana Hrudayalaya Ltd.

30 Jun 2025

1731.50

-0.35%

NARAYANA HRUDAYALAYA LIMITED

Sell: Narayana Hrudayalaya Ltd.

Recommendation Target

Geojit BNP Paribas

Narayana continues to deliver stable performance, driven by improved throughput rather than bed expansion. While the Indian business remained steady in FY25, the Cayman segment outperformed with 50% YoY sales growth and margin gains in Q4FY25. In our...

Narayana Hrudayalaya.. has an average target of 1781.75 from 4 brokers.

Narayana Hrudayalaya Ltd.

28 May 2025

1731.50

-0.35%

Narayana Hrudayalaya (NARH IN) Q4FY25 Result Update EBITDA...

Buy: Narayana Hrudayalaya Ltd.

Target

Prabhudas Lilladhar

Rs650mn losses in FY25 from its clinics and NHIC business. Q4FY25, 5% above our estimates aided by higher profitability across Cayman 28% QoQ. India business reported healthy EBITDA adjusted for NHIC losses, up 18% YoY. The management reiterated its aggressive capex plan and commitment towards growing throughput over the next 3-4 years through...

Narayana Hrudayalaya Ltd. is trading above its 200 day SMA of 1674.2

Narayana Hrudayalaya Ltd.

19 Feb 2025

1731.50

-0.35%

Narayana Hrudayalaya (NARH IN) Q3FY25 Result Update Good...

Buy: Narayana Hrudayalaya Ltd.

Target

Prabhudas Lilladhar

Booked Rs144mn of losses in Q3 from its clinics and insurance business Q3FY25, 9% above our estimates due to sharp ramp up in Cayman units. The India business reported healthy EBITDA adjusted for NHIC losses, up 15% YoY. The management reiterated its aggressive capex plan and commitment towards growing throughput over the next 3-4 years through debottlenecking,...

Number of FII/FPI investors increased from 277 to 335 in Jun 2025 qtr.

Narayana Hrudayalaya Ltd.

19 Feb 2025

1731.50

-0.35%

New Cayman unit faring well; maintaining a Buy

Buy: Narayana Hrudayalaya Ltd.

Anand Rathi

Lagging the consensus and in line with ARe, Narayana Hrudayalaya’s Q3 results were decent, revenue/EBITDA/PAT rising 14%/10%/3% y/y. Cayman reported Rs2.8bn/Rs1.2bn revenue/EBITDA, up 14/2% y/y.